Neurofibromatosis Type 1 | CHOP Research Institute
 

Neurofibromatosis Type 1

Neurofibromatosis 1 Optic Glioma's - Understanding the mechanisms of Vision Loss for Visual Restoration Strategies

Neurofibromatosis 1 Optic Glioma's - Understanding the mechanisms of Vision Loss for Visual Restoration Strategies

In this study we are seeking to learn how different eye tests and devices can help understand vision in patients with NF1, including how vision loss might show up on different eye imaging devices that measure the nerves or the blood vessels of the eye.

Cornerstone Blog

Hack-a-thon Reveals Unexpected Collaboration With Airline Industry Volunteers

Published on
Oct 27, 2021
CHOP and Airline Industry Employees Collaborate in Hack-a-thon
A rare disease hack-a-thon leads to an unusual collaboration between D3b’s bioinformaticians, including Adam Resnick, PhD, and American Airlines’ software engineers.
Cornerstone Blog

Does Cabozantinib Treat Plexiform Neurofibromas in Neurofibromatosis Type 1?

Published on
Feb 26, 2021
Snapshot Science: Does Cabozantinib Treat Plexiform Neurofibromas?
Data from a phase-2 study show that cabozantinib effectively treats plexiform neurofibromas in patients with neurofibromatosis type 1.
Amish C. Shah, MD, PhD
Amish C. Shah

Dr. Shah's clinical research interests are focused in the areas of neurofibromatosis type 1 and retinoblastoma. These studies range from translational studies to clinical trials of novel therapeutics to international consortiums studying long-term effects of therapy.

E-mail:
shahac [at] chop.edu